10x Genomics, Inc.
NASDAQ:TXGMedical - Healthcare Information Services
+$2.49 today
- Market cap
- $6.93B
- Beta
- 2.11
- P/E (TTM)
- -196.0
- EPS (TTM)
- -$0.18
Volume 2.10M
Average 3.06M
TXG EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
10x Genomics, Inc.NASDAQ: TXG
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA remains negative
Q3 FY2026 EBITDA was -$16.06M, compared with -$15.95M a year earlier. Trailing-twelve-month EBITDA was $37.56M.
Context
- EBITDA amounted to 0.6% of revenue in FY2025, down 21.3 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 11 analysts of -$30.39M (-877.3%) for the fiscal year ending Dec 2026, a slowdown from the +102.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$16.06M-78.8% QoQ
- Last fiscal yearDec 2025
- $3.91M+102.9% YoY
- LTMSep 2026
- $37.56M+221.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -0.7% | -129.4% | -128.7 pp |
| 1 year | +102.9% | -877.3% | -980.2 pp |
| 3-year CAGR | — | +33.3% | — |
| 5-year CAGR | +99.9% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 3.91M USD
- Year-over-year change
- +102.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.91M | +102.9% |
| FY2024 | 2024-12-31 | (133.99M) | +34.7% |
| FY2023 | 2023-12-31 | (205.11M) | -59.6% |
| FY2022 | 2022-12-31 | (128.49M) | -422.4% |
| FY2021 | 2021-12-31 | (24.6M) | — |
EBITDA vs competitors
How TXG compares with its peers on the latest reported figures
- TXG's LTM Sep 2026 EBITDA of $37.56M is the 7th highest of the 9 companies compared; the peer median is $609.04M.
- Its year-over-year change of +221.9% is the highest of 9, against a peer median of -4.2%.
- EBITDA amounts to 6.1% of revenue for TXG, versus a peer median of 27.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $2.04B | +13.2% | -1.2% | 27.6% | |
| LTM Jun 2026 | $1.36B | -23.6% | — | 30.3% | |
| LTM Jul 2026 | $767M | -6.7% | -13.5% | 26.3% | |
| LTM Jun 2026 | $703.39M | -1.6% | -2.7% | 33.5% | |
| LTM Jun 2026 | $514.7M | -22.7% | — | 19.9% | |
| LTM Sep 2026 | $328.77M | +48.3% | -9.1% | 26.8% | |
| LTM Sep 2026 | $37.56M | +221.9% | — | 6.1% | |
| LTM Mar 2026 | -$81.51M | +5.7% | — | 94.5% | |
| LTM Sep 2026 | -$129.8M | -149.9% | — | 28.3% | |
| Peer median (excluding TXG) | $609.04M | -4.2% | -5.9% | 27.9% | |
Competitors are the stored peer set for TXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 490.49M | 516.41M | 618.73M | 610.79M | 642.82M |
| Cost of Revenue | 74.09M | 120.39M | 209.41M | 196.3M | 198.94M |
| Gross Profit | 416.4M | 396.02M | 409.31M | 414.48M | 443.88M |
| Gross Margin | 84.9% | 76.7% | 66.2% | 67.9% | 69.1% |
| Research & Development | 211.75M | 265.67M | 270.33M | 264.7M | 238.63M |
| Selling, General & Admin | 257.56M | 298.3M | 343.33M | 344.34M | 316.13M |
| Operating Expenses | 469.31M | 563.97M | 674.64M | 609.04M | 554.77M |
| Depreciation & Amortization | 28.25M | 33.01M | 43.62M | 43.71M | 43.82M |
| EBITDA | (24.6M) | (128.49M) | (205.11M) | (133.99M) | 3.91M |
| EBITDA Margin | -5.0% | -24.9% | -33.2% | -21.9% | 0.6% |
| Operating Income | (52.91M) | (167.94M) | (265.33M) | (194.56M) | (110.89M) |
| Operating Margin | -10.8% | -32.5% | -42.9% | -31.9% | -17.2% |
| Interest Income | 206K | 6.65M | 16.91M | 18.45M | 20.05M |
| Interest Expense | 866K | 476K | 33K | 4K | 0 |
| Other Income / Expenses | (802K) | 5.97M | 16.57M | 16.86M | 70.98M |
| Income Before Tax | (53.72M) | (161.97M) | (248.76M) | (177.7M) | (39.91M) |
| Pre-Tax Margin | -11.0% | -31.4% | -40.2% | -29.1% | -6.2% |
| Income Tax Expense | 4.51M | 4.03M | 6.34M | 4.93M | 3.64M |
| Net Income | (58.22M) | (166M) | (255.1M) | (182.63M) | (43.54M) |
| Net Margin | -11.9% | -32.1% | -41.2% | -29.9% | -6.8% |
| EPS (Basic) | (0.53) | (1.46) | (2.18) | (1.52) | (0.35) |
| EPS (Diluted) | (0.53) | (1.46) | (2.18) | (1.52) | (0.35) |
| Weighted Avg Shares | 110.35M | 113.86M | 117.17M | 120.45M | 124.75M |
| Weighted Avg Shares (Diluted) | 110.35M | 113.86M | 117.17M | 120.45M | 124.75M |
10x Genomics, Inc.
NASDAQ:TXG
Intrinsic Alpha fair value
Locked
Current Price
$57.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.